Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Taylor Wimpey reiterates outlook on robust demand

(Sharecast News) - Taylor Wimpey said on Wednesday its spring selling season was progressing well, leaving it on track to meet full-year forecasts. Updating on trading, the blue chip house builder said it was seeing good levels of customer interest, despite recent macroeconomic volatility and ongoing affordability issues.

Net private sales for the year to 27 April were 0.77 per outlet per week, compared to 0.74 a year previously. The cancellation rate rose to 16% from 13%, however.

The total order book value as at 27 April was £2.36bn, representing 8,153 homes.

Taylor Wimpey said: "We have delivered a resilient sales rate in the year to date, which is consistent with our full-year UK completions guidance range of 10,400 to 10,800, excluding joint ventures."

Jennie Daly, chief executive, said: "The spring selling season has progressed in line with expectations, with good levels of customer demand reflected in our sales rate.

"As a result, we are today reiterating our guidance for full-year UK completions and UK group operating profit.

"Notwithstanding the wider macroeconomic backdrop, affordability is improving with lenders remaining committed to the housing market, albeit first-time buyers continue to experience some challenges."

Full-year profits are forecast to come in at around £444m.

Taylor Wimpey warned at its full-year results in February that the interim operating margin would likely be lower year-on-year, due to the impact of underlying pricing in the order book flowing through to completions in the period, as well as rising building cost inflation.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.